Relationship between weight status and anti-malarial drug efficacy and safety in children in Mali

Djimde, Moussa; Samouda, Hanen; Jacobs, Julien; Niangaly, Hamidou; Tekete, Mamadou; Sombie, Seydou B.; Mgina, Erick Josephat; Fofana, Bakary; Sagara, Issaka; Doumbo, Ogobara K.; Vaillant, Michel; Djimde, Abdoulaye A.

doi:10.1186/s12936-019-2673-6

Malaria Journal

Table 4 Multivariate analysis showing the association between baseline weight status and treatment arms and the evolution of alanine aminotransferase, aspartate aminotransferase, creatinine and haemoglobin levels

From: Relationship between weight status and anti-malarial drug efficacy and safety in children in Mali

	Alanine aminotransferase (ALAT)			Aspartate aminotransferase (ASAT)			Creatinine level			Haemoglobin level
	Estimate	Std. error	p-value	Estimate	Std. error	p-value	Estimate	Std. error	p-value	Estimate	Std. error	p-value
Enrolment: before treatment
Intercept	17.18	3.06	2.7e−08	41.31	4.45	< 2e−16	0.63	0.09	1.44e−11	10.16	0.40	< 2e−16
Weight deficiency	3.88	3.26	0.23	− 3.62	4.75	0.44	0.05	0.09	0.59	0.52	0.43	0.23
Overweight	3.25	3.36	0.34	0.56	4.87	0.90	− 0.05	0.10	0.65	− 0.53	0.44	0.23
AS + SP	− 1.29	3.96	0.74	− 11.42	5.79	0.04	− 0.04	0.12	0.73	− 0.89	0.52	0.09
AS	2.31	3.93	0.56	− 3.56	5.67	0.53	− 0.07	0.13	0.58	0.05	0.52	0.93
Weight deficiency * AS + SP	1.59	4.27	0.71	12.47	6.25	0.04	− 0.07	0.13	0.61	0.96	0.56	0.09
Over weight * AS + SP	− 0.42	4.46	0.92	8.45	6.48	0.19	0.003	0.14	0.98	0.89	0.58	0.13
Weight deficiency * AS	− 0.24	4.24	0.32	2.63	6.11	0.66	− 0.01	0.14	0.92	− 0.34	0.56	0.54
Over weight * AS	0.72	4.48	0.87	5.04	6.46	0.43	0.01	0.15	0.92	0.11	0.59	0.86
7 Days after treatment
Intercept	20.08	2.62	5.33e−14	31.14	3.56	< 2e−16	0.63	0.07	< 2e−16	9.62	0.37	< 2e−16
Weight deficiency	0.18	2.79	0.95	0.60	3.80	0.87	− 0.07	0.07	0.33	0.66	0.39	0.09
Overweight	1.71	2.88	0.55	8.81	3.91	0.02	− 0.06	0.07	0.40	− 0.38	0.40	0.35
AS + SP	− 1.89	3.39	0.58	− 0.89	4.58	0.85	− 0.07	0.08	0.36	− 0.55	0.47	0.24
AS	− 0.59	3.34	0.86	5.58	4.55	0.22	− 0.21	0.09	0.02	0.13	0.47	0.79
Weight deficiency * AS + SP	2.01	3.66	0.58	0.28	4.95	0.95	0.11	0.09	0.21	0.35	0.51	0.49
Overweight * AS + SP	− 0.81	3.82	0.83	− 3.14	5.16	0.54	0.07	0.09	0.46	0.54	0.53	0.31
Weight deficiency * AS	− 1.32	3.61	0.71	− 3.13	4.91	0.52	0.19	0.09	0.05	− 0.63	0.51	0.21
Over weight * AS	− 1.15	3.81	0.76	− 8.04	5.18	0.12	0.23	0.10	0.03	− 0.10	0.53	0.85
14 Days after treatment
Intercept	22.24	2.61	< 2e−16	38.19	3.44	< 2e−16	0.58	0.07	< 2e−16	10.63	0.34	< 2e−16
Weight deficiency	− 1.07	2.79	0.70	− 4.40	3.66	0.23	− 0.02	0.07	0.75	0.26	0.37	0.48
Overweight	0.24	2.87	0.93	0.81	3.77	0.83	− 0.04	0.08	0.61	− 0.60	0.38	0.11
AS + SP	− 5.50	3.39	0.11	− 6.50	4.41	0.14	− 0.06	0.08	0.44	− 1.13	0.44	0.01
AS	− 3.35	3.34	0.32	− 0.94	4.35	0.83	− 0.13	0.08	0.12	− 0.58	0.44	0.19
Weight deficiency * AS + SP	3.56	3.66	0.33	6.24	4.75	0.19	0.05	0.09	0.57	1.02	0.48	0.03
Over weight * AS + SP	0.24	3.82	0.95	4.54	4.96	0.36	0.09	0.09	0.33	1.02	0.50	0.04
Weight deficiency * AS	1.55	3.61	0.67	2.07	4.68	0.66	0.10	0.09	0.26	0.12	0.47	0.81
Over weight * AS	− 1.26	3.81	0.74	− 2.43	4.94	0.62	0.15	0.09	0.13	0.55	0.50	0.27

AS + SP: artesunate + sulfadoxine–pyrimethamine; AS: artesunate used in monotherapy
Significant p-values are given in italic

Back to article page

ISSN: 1475-2875

Contact us

Submission enquiries: journalsubmissions@springernature.com